Rescue therapy of difficult-to-treat indwelling central venous catheter-related bacteremias in cancer patients: A review for practical purposes

Expert Review of Anti-Infective Therapy

Volumn 11, Issue 2, 2013, Pages 179-186

  Castagnola, Elio ^a   Ginocchio, Francesca ^a  

^a G GASLINI INSTITUTE   (Italy)

Author keywords

antibiotics; antifungal; bacteremia; catheter lock; ethanol; HCl; indwelling central venous catheter; taurolidine

Indexed keywords

AMIKACIN; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; AMPICILLIN; ANTIBIOTIC AGENT; BETA LACTAM; CASPOFUNGIN; CEFTAZIDIME; CIPROFLOXACIN; DAPTOMYCIN; GENTAMICIN; HEPARIN; LINEZOLID; MICAFUNGIN; UROKINASE; VANCOMYCIN;

ADJUVANT THERAPY; BACILLUS; BACTEREMIA; CANCER PATIENT; CANDIDA ALBICANS; CANDIDA PARAPSILOSIS; CANDIDIASIS; CATHETER INFECTION; CATHETER REMOVAL; CENTRAL VENOUS CATHETER; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CONTINUOUS INFUSION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESPONSE; HUMAN; INDWELLING CATHETER; INFECTION RISK; MICROCOCCUS; NONHUMAN; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PROPIONIBACTERIACEAE; PSEUDOMONAS AERUGINOSA; REVIEW; RISK ASSESSMENT; RISK FACTOR; STAPHYLOCOCCUS EPIDERMIDIS; YARROWIA LIPOLYTICA;

ANTI-BACTERIAL AGENTS; BACTEREMIA; CATHETER-RELATED INFECTIONS; CATHETERS, INDWELLING; CHEMOTHERAPY, ADJUVANT; HUMANS; MICROBIAL SENSITIVITY TESTS; NEOPLASMS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84873916663     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.12.160     Document Type: Review

References (83)

1. Maki DG, Kluger DM, Crnich CJ. The risk of bloodstream infection in adults with different intravascular devices: a systematic review of 200 published prospective studies. Mayo Clin. Proc. 81(9), 1159-1171 (2006).
2. Viscoli C, Castagnola E. Prophylaxis and empirical therapy of infection in cancer patients. In:Principles and Practice of Infectious Diseases . Mandell GL, Bennett JE, Dolin R (Eds). Chirchill-Livingstone Elsevier, PA, USA, 3793-3807 (2010).
3. O'Grady NP, Alexander M, Burns LA et al.; Healthcare Infection Control Practices Advisory Committee (HICPAC). Guidelines for the prevention of intravascular catheter-related infections. Clin. Infect. Dis. 52(9), e162-e193 (2011).
4. Wolf HH, Leithauser M, Maschmeyer G et al.; Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Central venous catheter-related infections in hematology and oncology: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann. Hematol. 87(11), 863-876 (2008).
5. Mermel LA, Allon M, Bouza E et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin. Infect. Dis. 49(1), 1-45 (2009).
6. Robinson JL, Tawfik G, Roth A. Barriers to antibiotic lock therapy in children with intravascular catheter-related bloodstream infections. Pediatr. Infect. Dis. J. 24(10), 944 (2005).
7. diseases. 7 Toltzis P. Antibiotic lock technique to reduce central venous catheter-related bacteremia. Pediatr. Infect. Dis. J. 25(5), 449-450 (2006).
8. Solter E et al. Catheterassociated bloodstream infections in pediatric hematology-oncology patients: factors associated with catheter removal and recurrence. J. Pediatr. Hematol. Oncol. 28(1), 23-28 (2006).
9. Flynn PM, Willis B, Gaur AH, Shenep JL. Catheter design influences recurrence of catheter-related bloodstream infection in children with cancer. J. Clin. Oncol. 21(18), 3520-3525 (2003).
10. Polgreen PM, Beekmann SE, Diekema DJ, Sherertz RJ. Wide variability in the use of antimicrobial lock therapy and prophylaxis among infectious diseases consultants. Infect. Control Hosp. Epidemiol. 31(5), 554-557 (2010).
11. Rijnders BJ, Van Wijngaerden E, Vandecasteele SJ, Stas M, Peetermans WE. Treatment of long-term intravascular catheter-related bacteraemia with antibiotic lock: randomized, placebo-controlled trial. J. Antimicrob. Chemother. 55(1), 90-94 (2005).
12. Treatment of long-term intravascular catheter-related bacteraemia with antibiotic-lock therapy. J. Antimicrob. Chemother. 58(4), 816-821 (2006).
13. Vergidis P, Patel R. Novel approaches to the diagnosis, prevention, and treatment of medical device-associated infections. Infect. Dis. Clin. North Am. 26, 173-186 (2012).
14. De Pauw B, Walsh TJ, Donnelly JP et al.; European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis. 46(12), 1813-1821 (2008).
15. Castagnola E, Bandettini R, Lorenzi I, Caviglia I, Macrina G, Tacchella A. Catheter-related bacteremia caused by methicillin-resistant coagulase negative staphylococci with elevated minimal inhibitory concentration for vancomycin. Pediatr. Infect. Dis. J. 29(11), 1047-1048 (2010).
16. Donlan RM. Biofilms on central venous catheters: is eradication possible? Curr. Top. Microbiol. Immunol. 322, 133-161 (2008).
17. Oncu S, Oncu S, Ozturk B, Kurt I, Sakarya S. Elimination of intraluminal colonization by antibiotic lock in catheters. Tohoku J. Exp. Med. 203(1), 1-8 (2004).
18. Lee JY, Ko KS, Peck KR, Oh WS, Song JH. In vitro evaluation of the antibiotic lock technique (ALT) for the treatment of catheter-related infections caused by staphylococci. J. Antimicrob. Chemother. 57(6), 1110-1115 (2006).
19. Haimi-Cohen Y, Husain N, Meenan J, Karayalcin G, Lehrer M, Rubin LG. Vancomycin and ceftazidime bioactivities persist for at least 2 weeks in the lumen in ports: simplifying treatment of port-associated bloodstream infections by using the antibiotic lock technique. Antimicrob. Agents Chemother. 45(5), 1565-1567 (2001).
20. Droste JC, Jeraj HA, MacDonald A, Farrington K. Stability and in vitro efficacy of antibiotic-heparin lock solutions potentially useful for treatment of central venous catheter-related sepsis. J. Antimicrob. Chemother. 51(4), 849-855 (2003).
21. Elwood RL, Spencer SE. Successful clearance of catheter-related bloodstream infection by antibiotic lock therapy using ampicillin. Ann. Pharmacother. 40(2), 347-350 (2006).
22. Vercaigne LM, Sitar DS, Penner SB, Bernstein K, Wang GQ, Burczynski FJ. Antibiotic-heparin lock: in vitro antibiotic stability combined with heparin in a central venous catheter. Pharmacotherapy 20(4), 394-399 (2000).
23. Robinson JL, Tawfik G, Saxinger L, Stang L, Etches W, Lee B. Stability of heparin and physical compatibility of heparin/ antibiotic solutions in concentrations appropriate for antibiotic lock therapy. J. Antimicrob. Chemother. 56(5), 951-953 (2005).
24. Anthony TU, Rubin LG. Stability of antibiotics used for antibiotic-lock treatment of infections of implantable venous devices (ports). Antimicrob. Agents Chemother. 43(8), 2074-2076 (1999).
25. Giacometti A, Cirioni O, Ghiselli R et al. Comparative efficacies of quinupristindalfopristin, linezolid, vancomycin, and ciprofloxacin in treatment, using the antibiotic-lock technique, of experimental catheter-related infection due to Staphylococcus aureus. Antimicrob. Agents Chemother. 49(10), 4042-4045 (2005).
26. Curtin J, Cormican M, Fleming G, Keelehan J, Colleran E. Linezolid compared with eperezolid, vancomycin, and gentamicin in an in vitro model of antimicrobial lock therapy for Staphylococcus epidermidis central venous catheter-related biofilm infections. Antimicrob. Agents Chemother. 47(10), 3145-3148 (2003).
27. Maiefski M, Rupp ME, Hermsen ED. Ethanol lock technique: review of the literature. Infect. Control Hosp. Epidemiol. 30(11), 1096-1108 (2009).
28. Bookstaver PB, Gerrald KR, Moran RR. Clinical outcomes of antimicrobial lock solutions used in a treatment modality: a retrospective case series analysis. Clin. Pharmacol. 2, 123-130 (2010).
29. Karaaslan H, Peyronnet P, Benevent D, Lagarde C, Rince M, Leroux-Robert C. Risk of heparin lock-related bleeding when using indwelling venous catheter in haemodialysis. Nephrol. Dial. Transplant. 16(10), 2072-2074 (2001).
30. Weijmer MC, van den Dorpel MA, Van de Ven PJ et al.; CITRATE Study Group. Randomized, clinical trial comparison of trisodium citrate 30% and heparin as catheter-locking solution in hemodialysis patients. J. Am. Soc. Nephrol. 16(9), 2769-2777 (2005).
31. Kishimoto TK, Viswanathan K, Ganguly T et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N. Engl. J. Med. 358(23), 2457-2467 (2008).
32. Reimund JM, Arondel Y, Finck G, Zimmermann F, Duclos B, Baumann R. Catheter-related infection in patients on home parenteral nutrition: results of a prospective survey. Clin. Nutr. 21(1), 33-38 (2002).
33. Messing B, Man F, Colimon R, Thuillier F, Beliah M. Antibiotic-lock technique is an effective treatment of bacterial catheterrelated sepsis during parenteral nutrition. Clin. Nutr. 9(4), 220-225 (1990).
34. Grau S, Gil MJ, Mateu-de Antonio J, Pera M, Marin-Casino M. Antibiotic-lock technique using daptomycin for subcutaneous injection ports in a patient on home parenteral nutrition. J. Infect. 59(4), 298-299 (2009).
35. Chauhan A, Lebeaux D, Ghigo JM, Beloin C. Full and broad-spectrum in vivo eradication of catheter-associated biofilms using gentamicin-EDTA antibiotic lock therapy. Antimicrob. Agents Chemother. 56(12), 6310-6318 (2012).
36. Bookstaver PB, Williamson JC, Tucker BK, Raad II, Sherertz RJ. Activity of novel antibiotic lock solutions in a model against isolates of catheter-related bloodstream infections. Ann. Pharmacother. 43(2), 210-219 (2009).
37. Castagnola E, Moroni C, Gandullia P et al. Catheter lock and systemic infusion of linezolid for treatment of persistent Broviac catheter-related staphylococcal bacteremia. Antimicrob. Agents Chemother. 50(3), 1120-1121 (2006).
38. Buckler BS, Sams RN, Goei VL et al. Treatment of central venous catheter fungal infection using liposomal amphotericin-B lock therapy. Pediatr. Infect. Dis. J. 27(8), 762-764 (2008).
39. Castagnola E, Marazzi MG, Tacchella A, Giacchino R. Broviac catheter-related candidemia. Pediatr. Infect. Dis. J. 24(8), 747 (2005).
40. Viale P, Petrosillo N, Signorini L, Puoti M, Carosi G. Should lock therapy always be avoided for central venous catheter- associated fungal bloodstream infections? Clin. Infect. Dis. 33(11), 1947-1948; author reply 1949 (2001).
41. Bachmann SP, VandeWalle K, Ramage G et al. In vitro activity of caspofungin against Candida albicans biofilms. Antimicrob. Agents Chemother. 46(11), 3591-3596 (2002).
42. Ramage G, VandeWalle K, Bachmann SP, Wickes BL, Lopez-Ribot JL. In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. Antimicrob. Agents Chemother. 46(11), 3634-3636 (2002).
43. Soustre J, Rodier MH, Imbert-Bouyer S, Daniault G, Imbert C. Caspofungin modulates in vitro adherence of Candida albicans to plastic coated with extracellular matrix proteins. J. Antimicrob. Chemother. 53(3), 522-525 (2004).
44. Cateau E, Berjeaud JM, Imbert C. Possible role of azole and echinocandin lock solutions in the control of Candida biofilms associated with silicone. Int. J. Antimicrob. Agents 37(4), 380-384 (2011).
45. Stevens DA, Espiritu M, Parmar R. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob. Agents Chemother. 48(9), 3407-3411 (2004).
46. Ozdemir H, Karbuz A, Ciftci E et al. Successful treatment of central venous catheter infection due to Candida lipolytica by caspofungin-lock therapy. Mycoses 54(5), e647-e649 (2011).
47. Cateau E, Rodier MH, Imbert C. In vitro efficacies of caspofungin or micafungin catheter lock solutions on Candida albicans biofilm growth. J. Antimicrob. Chemother. 62(1), 153-155 (2008).
48. Ko KS, Lee JY, Song JH, Peck KR. In vitro evaluation of antibiotic lock technique for the treatment of Candida albicans, C. glabrata, and C. tropicalis biofilms. J. Korean Med. Sci. 25(12), 1722-1726 (2010).
49. Oncu S. In vitro effectiveness of antifungal lock solutions on catheters infected with Candida species. J. Infect. Chemother. 17(5), 634-639 (2011).
50. Koldehoff M, Zakrzewski JL. Taurolidine is effective in the treatment of central venous catheter-related bloodstream infections in cancer patients. Int. J. Antimicrob. Agents 24(5), 491-495 (2004).
51. Haag GM, Berger AK, Jager D. Treatment of long-term catheter-related bloodstream infections with a taurolidine block: a single cancer center experience. J. Vasc. Access 12(3), 244-247 (2011).
52. Barbaric D, Curtin J, Pearson L, Shaw PJ. Role of hydrochloric acid in the treatment of central venous catheter infections in children with cancer. Cancer 101(8), 1866-1872 (2004).
53. Larsen LN, Malchau E, Kristensen B, Schroeder H. Hydrochloric acid treatment of tunneled central venous catheter infections in children with cancer. J. Pediatr. Hematol. Oncol. 33(2), e64-e68 (2011).
54. Dannenberg C, Bierbach U, Rothe A, Beer J, Korholz D. Ethanol-lock technique in the treatment of bloodstream infections in pediatric oncology patients with broviac catheter. J. Pediatr. Hematol. Oncol. 25(8), 616-621 (2003).
55. McGrath EJ, Salloum R, Chen Y et al. Short-dwell ethanol lock therapy in children is associated with increased clearance of central line - associated bloodstream infections. Clin. Pediatr. 50, 943-951 (2011).
56. Onland W, Shin CE, Fustar S, Rushing T, Wong WY. Ethanol-lock technique for persistent bacteremia of long-term intravascular devices in pediatric patients. Arch. Pediatr. Adolesc. Med. 160(10), 1049-1053 (2006).
57. Sauer K, Steczko J, Ash SR. Effect of a solution containing citrate/methylene blue/parabens on Staphylococcus aureus bacteria and biofilm, and comparison with various heparin solutions. J. Antimicrob. Chemother. 63(5), 937-945 (2009).
58. Passerini de Rossi B, Feldman L, Pineda MS, Vay C, Franco M. Comparative in vitro efficacies of ethanol-, EDTA- and levofloxacin-based catheter lock solutions on eradication of Stenotrophomonas maltophilia biofilms. J. Med. Microbiol. 61, 1248-1253 (2012).
59. Ghannoum MA, Isham N, Jacobs MR. Antimicrobial activity of B-lock against bacterial and Candida spp. causing catheter-related bloodstream infections. Antimicrob. Agents Chemother. 55(9), 4430-4431 (2011).
60. Raad II, Hachem RY, Hanna HA et al. Role of ethylene diamine tetra-acetic acid (EDTA) in catheter lock solutions: EDTA enhances the antifungal activity of amphotericin B lipid complex against Candida embedded in biofilm. Int. J. Antimicrob. Agents 32(6), 515-518 (2008).
61. Raad I, Hanna H, Dvorak T, Chaiban G, Hachem R. Optimal antimicrobial catheter lock solution, using different combinations of minocycline, EDTA, and 25-percent ethanol, rapidly eradicates organisms embedded in biofilm. Antimicrob. Agents Chemother. 51(1), 78-83 (2007).
62. Sherertz RJ, Boger MS, Collins CA, Mason L, Raad II. Comparative in vitro efficacies of various catheter lock solutions. Antimicrob. Agents Chemother. 50(5), 1865-1868 (2006).
63. Venkatesh M, Rong L, Raad I, Versalovic J. Novel synergistic antibiofilm combinations for salvage of infected catheters. J. Med. Microbiol. 58(Pt 7), 936-944 (2009).
64. Ferreira Chacon JM, Hato de Almeida E, de Lourdes Simoes R et al. Randomized study of minocycline and edetic acid as a locking solution for central line (port-acath) in children with cancer. Chemotherapy 57(4), 285-291 (2011).
65. Shah CB, Mittelman MW, Costerton JW et al. Antimicrobial activity of a novel catheter lock solution. Antimicrob. Agents Chemother. 46(6), 1674-1679 (2002).
66. Viale P, Pagani L, Petrosillo N et al.; Italian Hospital and HIV Infection Group. Antibiotic lock-technique for the treatment of catheter-related bloodstream infections. J. Chemother. 15(2), 152-156 (2003).
67. Gazarian M, Kelly M, McPhee JR, Graudins LV, Ward RL, Campbell TJ. Off-label use of medicines: consensus recommendations for evaluating appropriateness. Med. J. Aust. 185(10), 544-548 (2006).
68. Jones GR, Konsler GK, Dunaway RP. Urokinase in the treatment of bacteremia and candidemia in patients with right atrial catheters. Am. J. Infect. Control 24(3), 160-166 (1996).
69. La Quaglia MP, Caldwell C, Lucas A et al. A prospective randomized double-blind trial of bolus urokinase in the treatment of established Hickman catheter sepsis in children. J. Pediatr. Surg. 29(6), 742-745 (1994).
70. Pession A, Castellini C, Prete A, Locatelli F, Urbini B, Paolucci G. Method using urokinase and an antibiotic to avoid device removal in central venous catheter-related infections. Med. Pediatr. Oncol. 35(4), 434-435 (2000).
71. Jones GR, Konsler GK, Dunaway RP, Lacey SR, Azizkhan RG. Prospective analysis of urokinase in the treatment of catheter sepsis in pediatric hematology-oncology patients. J. Pediatr. Surg. 28(3), 350-355; discussion 355 (1993).
72. De Sio L, Jenkner A, Milano GM et al. Antibiotic lock with vancomycin and urokinase can successfully treat colonized central venous catheters in pediatric cancer patients. Pediatr. Infect. Dis. J. 23(10), 963-965 (2004).
73. Atkinson JB, Chamberlin K, Boody BA. A prospective randomized trial of urokinase as an adjuvant in the treatment of proven Hickman catheter sepsis. J. Pediatr. Surg. 33(5), 714-716 (1998).
74. MacGowan A. Revisiting ?-lactams - PK/PD improves dosing of old antibiotics. Curr. Opin. Pharmacol. 11(5), 470-476 (2011).
75. Cataldo MA, Tacconelli E, Grilli E, Pea F, Petrosillo N. Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis. J. Antimicrob. Chemother. 67(1), 17-24 (2012).
76. Chua K, Howden BP. Treating Grampositive infections: vancomycin update and the whys, wherefores and evidence base for continuous infusion of anti-Gram-positive antibiotics. Curr. Opin. Infect. Dis. 22(6), 525-534 (2009).
77. James JK, Palmer SM, Levine DP, Rybak MJ. Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented Gram-positive infections. Antimicrob. Agents Chemother. 40(3), 696-700 (1996).
78. Adembri C, Novelli A. Pharmacokinetic and pharmacodynamic parameters of antimicrobials: potential for providing dosing regimens that are less vulnerable to resistance. Clin. Pharmacokinet. 48, 517-528 (2009).
79. Hollenstein U, Brunner M, Mayer BX et al. Target site concentrations after continuous infusion and bolus injection of cefpirome to healthy volunteers. Clin. Pharmacol. Ther. 67(3), 229-236 (2000).
80. Bourgoin A, Leone M, Martin C. Role of glycopeptides in the treatment of septic complications after cardiac surgery. J. Chemother. 13(1), 112-118 (2001).
81. Sampedro MF, Patel R. Infections associated with long-term prosthetic devices. Infect. Dis. Clin. North Am. 21(3), 785-819 (2007).
82. Giacchino M, Bezzio S, Chiapello N et al. Continuous antibiotic infusion for salvage therapy of partially implanted central venous catheter tunnel infections due to staphylococci. Pediatr. Blood Cancer 48, 35-38 (2007).
83. Benezra D, Kiehn TE, Gold JW, Brown AE, Turnbull AD, Armstrong D. Prospective study of infections in indwelling central venous catheters using quantitative blood cultures. Am. J. Med. 85(4), 495-498 (1988).